Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genzyme companies transfer cancer diagnostic IP (intellectual property):

This article was originally published in Clinica

Executive Summary

Genzyme Genetics has bought rights relating to IP and licences for cancer diagnostics from Genzyme Molecular Oncology for $32 million and up to $1 million in milestone payments. Both companies are business units of Cambridge, Massachusetts-based Genzyme General. Genzyme Genetics plans to use the acquired assets to develop and commercialise new specialised tests for a wide range of cancers. Genzyme Genetics also assumes exclusive rights to IP for cancer-related genes and diagnostic methods. As a result of this and other deals, Genzyme Molecular has around $40 million in cash, enough to fund operations into next year.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts